FORM 4 o Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number:        3235-0287 Expires: January 31, 2005 Estimated average burden hours per response .... 0.5

---

1.

Name and Address of Reporting Person*

2.

Issuer Name and Ticker or Trading Symbol

6.

Relationship of Reporting Person(s) to Issuer (Check all applicable)

Hedrick

Marc

Hamilton

MacroPore Biosurgery, Inc.

X   Director

10% Owner

(Last)

(First)

(Middle)

3.

I.R.S. Identification Number of Reporting Person (voluntary)

4.

Statement for Month/Day/Year

X         Officer (give title below)

Other (specify below)

6740 Top Gun Street

November 14, 2002

Chief Scientific Officer, Medical Director

(Street)

5.

If Amendment, Date of Original (Month/Day/Year)

7.

Individual or Joint/Group Filing (Check Applicable Line)   X       Form filed by One Reporting Person          Form filed by More than

San Diego

CA

92121

11/15/2002

One Reporting Person

(City)

(State)

(Zip)

Table I — Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.

Title of Security (Instr. 3)

2.

Transaction Date

2A.

Deemed Execution Date, if any

3.

Transaction Code (Instr. 8)

4.

Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

5.

Amount of Securities Beneficially Owned Following Reported Transaction(s)

6.

Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7.

Nature of Indirect Beneficial Ownership (Instr. 4)

(Month/Day/Year)

(Month/Day/Year)

(Instr. 3 and 4)

Code

V

Amount

(A) or (D)

Price

Common Stock

11-13-02

A

435,525

A

(1)

435,525

D

---

Table II — Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

---

1.

Title of Derivative Security (Instr. 3)

2.

Conversion or Exercise Price of Derivative Security

3.

Transaction Date (Month/Day/Year)

3A.

Deemed Execution Date, if any (Month/Day/Year)

4.

Transaction Code (Instr. 8)

5.

Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

6.

Date Exercisable and Expiration Date (Month/Day/Year)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Employee Stock Option (Right To Buy)

4.15

11/14/02

A

150,000

12/14/02 (2)

11/14/12

7.		Title and Amount of Underlying Securities (Instr. 3 and 4)				8.		Price of Derivative Security (Instr. 5)		9.		Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10.		Ownership Form of Derivative Securities: Direct (D) or Indirect (I) (Instr. 4)		11.		Nature of Indirect Beneficial Ownership (Instr. 4)
		Title		Amount or Number of Shares
		Common Stock		150,000								150,000				D

Explanation of Responses: (1) Received in exchange for 1,985,401 shares of StemSource, Inc. common stock in connection with the merger of StemSource, Inc. into MacroPore Biosurgery, Inc. On the effective date of the merger the closing price of MacroPore Biosurgery's stock was $4.15 per share. (2) Employee Stock Options vest 1/48th each month from grant date.

Reminder:		Report on a separate line for each class of securities beneficially owned directly or indirectly.
*		If the form is filed by more than one reporting person, see Instruction 5(b)(v)
**		Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:		File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

http://www.sec.gov/divisions/corpfin/forms/form4.htm
Last update: 09/05/2002

---